KRAS and colorectal carcinoma: Similarly, another prominent genetic alteration in CRC, the Kirsten rat sarcoma viral oncogene homologue gene (KRAS) mutation, can increase the expression of CXCL3, thereby enhancing the migration of CXCR2+ TANs via the CXCL3−CXCR2 axis, and fostering resistance to anti-PD-1 immunotherapy in mice [33].